<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644653</url>
  </required_header>
  <id_info>
    <org_study_id>2020.384</org_study_id>
    <nct_id>NCT04644653</nct_id>
  </id_info>
  <brief_title>Ex Vivo Test of New Stroke Treatment Using Magnetic Nanorobots</brief_title>
  <official_title>Steered t-PA Delivery for Thrombolysis Test Using Magnetic Swarming Nanorobots on Human Placenta as an ex Vivo Model of Human Cerebral Vascular System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tissue plasminogen activator (tPA) is the FDA approved thrombolytic drug for patients with&#xD;
      acute ischemic stroke. While transcatheter endovascular therapy is widely accepted as an&#xD;
      effective method for targeted blood vessels via a catheter to elicit ischemic necrosis.&#xD;
&#xD;
      To improve targeting accuracy administrated tPA and avoiding collateral tissue damage, we&#xD;
      developed a magnetic nanorobotic system to active system to active intravenous delivery of&#xD;
      tPA for targeted thrombus removal. Here human placenta will be used as an ex vivo model for&#xD;
      human cerebral vascular system in our ex vivo thrombolysis study. Our magnetic nanorobotic&#xD;
      system encapsulated with tPA overcomes the limitations of passive thrombolytic therapy with&#xD;
      tPA alone and will be a promising approach for the treatment of ischemic stroke and other&#xD;
      thrombotic diseases&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombolysis performance</measure>
    <time_frame>1 -2 hours</time_frame>
    <description>Size of thrombus by angiography, mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time for recanalization</measure>
    <time_frame>1 -2 hours</time_frame>
    <description>Time for recanalization of occluded vessels, mins</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Damage to vessels</measure>
    <time_frame>1 -2 hours</time_frame>
    <description>Histological damage evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stability of magnetic nanorobots</measure>
    <time_frame>1 - 2 hours</time_frame>
    <description>Controllability of the magnetic nanorobots</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage requirement</measure>
    <time_frame>1 - 2 hours</time_frame>
    <description>Dosage requirement of nanorobots and thus t-PA, mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of administrated nanorobots</measure>
    <time_frame>1 - 2 hours</time_frame>
    <description>The distribution of administrated nanorobots</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thrombosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        -  Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirth&#xD;
             with natural delivery or caesarean sections after 37-42 weeks of gestation.&#xD;
&#xD;
          -  Healthy singleton pregnancy.&#xD;
&#xD;
          -  Participant able to give voluntary, written, informed consent to participate in the&#xD;
             study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirth&#xD;
             with natural delivery or caesarean sections after 37-42 weeks of gestation.&#xD;
&#xD;
          -  Healthy singleton pregnancy.&#xD;
&#xD;
          -  Participant able to give voluntary, written, informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal prenatal development (e.g intrauterine growth restriction)&#xD;
&#xD;
          -  Early preterm birth &lt; 37 weeks&#xD;
&#xD;
          -  Verbal Confirmation of hypercholesterolemia&#xD;
&#xD;
          -  Family history of stroke or vascular disease&#xD;
&#xD;
          -  Type I or Type II diabetes and gestational diabetes&#xD;
&#xD;
          -  Cancer, except skin cancers completely excised with no chemotherapy or radiation with&#xD;
             a follow up that is negative.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory results at screening.&#xD;
&#xD;
          -  Any other active or unstable medical condition.&#xD;
&#xD;
          -  History of liver disease.&#xD;
&#xD;
          -  History of hypertension (including pre-eclampsia)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Nanomaterials &amp; Microrobotics Laboratory, Room 202, William M.W Mong Engineering Building, CUHK and Room 508, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynaecology, Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pui Wah Chung, Doctor</last_name>
      <phone>(852) 35051537</phone>
      <email>jacquelinechung@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Pui Wah Chung, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>ZHANG Li</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

